Clearmind Medicine Announces FDA Clearance For IND Application Of MEAI-Based CMND-100 Oral Capsule; Phase I/IIa Clinical Trial For Alcohol Use Disorder To Proceed In The US; Trial Already Approved In Israel
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine has received FDA clearance for its IND application of the MEAI-based CMND-100 oral capsule. This allows the company to proceed with a Phase I/IIa clinical trial for alcohol use disorder in the US. The trial has already been approved in Israel.
July 16, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine has received FDA clearance for its IND application of the MEAI-based CMND-100 oral capsule, allowing the company to proceed with a Phase I/IIa clinical trial for alcohol use disorder in the US. The trial has already been approved in Israel.
FDA clearance is a significant milestone for Clearmind Medicine, as it allows the company to advance its clinical trials in the US. This regulatory approval is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100